Corbus Pharmaceuticals Holdings, Inc. CRBP PHARMA
Company Overview
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +10.48% |
| 6 Months: | +10.94% |
| 3 Months: | +40.15% |
| 1 Month: | +4.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)52.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 45.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRBP Corbus Pharmaceuticals Holdings, Inc. PHARMA | 10.60 | -1.73 | $205.02M | 0.00% | -57.84% | -95.58% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 853.65K | 1.09M | 1.89M | 29.09M | 2.59M | 1.76M | 286.35K | 1.23M | 647.82K | 136.56K | 97.32K | - | 0 | - | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -464.30K | -818.20K | -1.54M | -2.56M | -2.25M | -2.89M | -4.19M | -5.33M | -7.57M | -7.45M | -7.29M | -6.96M | -10.86M | -11.86M | -12.39M | -14.90M | -26.52M | 1.71M | -25.10M | -29.89M | -38.14M | -33.97M | -15.41M | -16.70M | -13.88M | - | -8.52M | -12.34M | -8.18M | -17.30M | -8.19M | -9.49M | -9.62M | -10.99M | -15.51M | -19.77M | -19.15M | -24.42M | -24.30M | -36.19M |
| Net Income | -504.61K | -659.62K | -1.54M | -2.56M | -2.25M | -2.89M | -4.19M | -5.35M | -7.57M | -7.47M | -7.30M | -6.97M | -10.69M | -11.70M | -12.07M | -14.60M | -26.23M | 2.15M | -20.79M | -29.66M | -38.11M | -34.90M | -16.07M | -17.14M | -2.18M | - | -9.44M | -13.25M | -8.78M | -17.74M | -8.78M | -10.05M | -6.90M | -10.00M | -13.78M | -16.98M | -17.66M | -23.34M | -22.97M | -35.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.21 | - | - | 0.03 | - | - | -0.52 | - | - | - | -0.02 | - | -2.26 | -3.18 | -2.11 | -4.24 | -2.05 | -2.27 | -0.83 | -0.90 | -1.15 | -1.39 | -1.44 | -1.90 | -1.23 | -1.81 |
| R&D Expense | 169.44K | 452.60K | 723.43K | 1.71M | 1.63M | 2.17M | 3.57M | 4.32M | 5.38M | 6.37M | 5.76M | 5.62M | 8.29M | 9.77M | 10.26M | 12.81M | 21.78M | 22.18M | 22.15M | 23.95M | 30.69M | 27.52M | 10.72M | 11.27M | 8.70M | 380.00K | 3.29M | 2.50M | 4.11M | 13.39M | 4.25M | 6.55M | 5.76M | 6.87M | 10.81M | 15.64M | 15.19M | 20.86M | 19.82M | 31.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 648.38K | 1.91M | 2.44M | 4.82M | 36.14M | 3.94M | 881.71K | 0 | - | - | - |
| Operating Income | -557.28K | -2.65M | -8.85M | -19.99M | -32.56M | -56.75M | -77.10M | -122.81M | -55.99M | -39.84M | -45.08M | -48.72M | -85.31M |
| Net Income | -602.35K | -2.54M | -8.85M | -20.00M | -32.42M | -55.67M | -71.45M | -111.27M | -45.64M | -42.35M | -44.60M | -40.21M | -78.54M |
| Diluted EPS | - | - | - | - | - | - | - | - | -11.15 | -10.15 | -10.31 | -3.68 | -5.90 |
| R&D Expense | 210.67K | 1.26M | 5.89M | 15.44M | 26.04M | 48.61M | 89.60M | 98.27M | 36.45M | 16.14M | 31.17M | 32.22M | 70.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 305.52K | 6.60M | 12.88M | 17.89M | 66.98M | 46.99M | 49.14M | 102.29M | 107.73M | 66.31M | 28.27M | 155.88M | 168.19M |
| Total Equity | -1.19M | -1.78M | 5.86M | 8.99M | 8.92M | 57.78M | 27.52M | 6.16M | 45.27M | 69.11M | 32.99M | -6.91M | 142.43M | 147.50M |
| Cash & Equivalents | 542.48K | 303.02K | 6.26M | 12.34M | 14.99M | 62.54M | 41.75M | 31.75M | 85.43M | 25.01M | 17.00M | 13.72M | 17.20M | 28.49M |
| Long Term Debt | - | - | - | - | - | - | - | - | 18.03M | 15.64M | 15.98M | 0 | - | - |
| Total Liabilities | - | 980.11K | 738.04K | 3.89M | 8.97M | 9.19M | 19.47M | 42.98M | 57.02M | 38.62M | 33.32M | 35.18M | 13.45M | 20.69M |
| Current Liabilities | - | 648.87K | 738.04K | 3.63M | 8.90M | 8.20M | 18.09M | 34.89M | 31.90M | 17.01M | 12.64M | 31.89M | 11.82M | 20.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -27.80M | -30.07M | -45.72M | -99.69M | -48.18M | -37.54M | -36.10M | -41.79M | -64.49M |
| Investing Cash Flow | - | - | - | -707.43K | -2.30M | -2.74M | -484.49K | -73.42M | 30.07M | 35.64M | -121.31M | -1.64M |
| Financing Cash Flow | - | - | - | 76.01M | 11.42M | 38.46M | 154.87M | 60.82M | -533.62K | -2.82M | 166.58M | 77.43M |
| Capital Expenditure | -64.45K | -114.04K | -353.03K | -707.43K | -2.30M | -2.74M | -484.49K | -54.17K | -13.45K | -0 | -0 | -7.00K |
| Free Cash Flow | - | - | - | -28.50M | -32.37M | -48.46M | -100.17M | -48.24M | -37.56M | -36.10M | -41.79M | -64.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,365.5% | -1,045.6% | -1,334.4% | -1,176.8% | -213.3% | -3,119.2% | -6,350.1% | - | - | - | - |
| Net Margin % | - | - | -1,365.1% | -1,046.3% | -1,328.6% | -1,154.5% | -197.7% | -2,826.1% | -5,176.4% | - | - | - | - |
| ROE % | 33.8% | -43.3% | -98.5% | -224.2% | -56.1% | -202.3% | -1,160.4% | -245.8% | -66.0% | -128.4% | 646.0% | -28.2% | -53.2% |
| ROCE % | 162.3% | -45.2% | -95.8% | -222.3% | -55.4% | -196.4% | -540.9% | -174.5% | -61.7% | -74.2% | 1,244.6% | -33.8% | -57.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 12.56% | 2.34M | $17.54M |
| 2 | Orbimed Advisors LLC. | 9.30% | 1.74M | $12.99M |
| 3 | Blackrock Inc. | 7.13% | 1.33M | $9.96M |
| 4 | Aberdeen Group plc | 7.08% | 1.32M | $9.89M |
| 5 | Vanguard Capital Management LLC | 4.08% | 760.94K | $5.69M |
| 6 | Jones Hill Capital LP | 3.50% | 653.57K | $4.89M |
| 7 | Prosight Management, Lp | 3.48% | 650.00K | $4.86M |
| 8 | Stonepine Capital Management, LLC | 2.28% | 425.00K | $3.18M |
| 9 | Geode Capital Management, LLC | 2.27% | 423.37K | $3.17M |
| 10 | Adar1 Capital Management, LLC | 2.26% | 421.79K | $3.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRBP
CRBP Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9vWUlBejZ4a2c4WHMyOTdFR2JFMmhQZE12a3VpaTlHdVFPRmNqN2d5MmE3XzhKSms3cHhkY09hUVBqbEdEYVV6Y1BaeFh3N2R6LWF5b2xwNC1ycWMyNmdmNFJyeEJsMl9DT3VFZ3REQmt6T0VuX2N1RmlR?oc=5" target="_blank">CRB…
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOaTRKOHN3bHp0blFXTEJQVnVZaDc0czJuZ2VoVkY0Q1dYdTNPczZGNm1rYmZ6Zjltb3RyLW9TTVNYN1NYZkVjemhZc1JtaEZhdFlleG5EZ0dCRklqdlhCYVAyaE93UFlPZXhwbjdtRVJTVU15YUlfLTRyb0JTRWw5SEthWkhUeUhTQlM2Vz…
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSWx3ek9qalJZU3F3V1Y3czBRRl8ydFd4ci1PMnpYclZtWUFwLVRmWUNBYUhIUC00dU9DRWllbzdqdnZ6TkhDMEJmTkR4cTR3Q0dEUkJJYU9BLTlhSWZFcDNkN3pVdGpTTEJaeTV5OGZSNXpLQ2p2UERqRmJzX2RvSDVRYTgwemFWa0lEZl…
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPSE1VMS1uV1NnZldoUG1VbXRRaHpCQ0F3c0dkWF9UTnRkem40LUhoR2lTRFJqV2J3bFZCQ1hISFhCQ016OVBKTktSZE83NVBrMzB6VlNnOXJKbHNiQk0zbDlrZG84NHJGTl9DcmhSemNVa0NKSDE3X0xaMl9ta3BFZEZBQ3FmTHJzWkdXLS…
Corbus Pharmaceuticals (CRBP) Is Down 19.6% After FDA Aligns On CRB-701 Registrational Strategy - Has The Bull Case Changed? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxNNTNyUTdyZ2Z5REhMZmpJaW1FSzEyOUlsMHM5VGdqQ3IydTRid21FSlhRbmpXYS1QNWdwX3lyT050MGFieWU1ZFl1cUVPUWZEOC01c3R1VlpWVFd2MVYtNy1IaU1nckFHNHFhWEhsVzdtTkZsMS1CazFtbE9PV0JIMk0yM2lDNVNUWTZucj…
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOSTJIcUhUN1FrS0FFZV9ZUEsySHVqWWJfd3RVQmtqbkQ4RGxFQm1icDhRZ0psYTVDZUlUdWVBVExuS2cwRF9tWU9oNk5wYkhWREUzMlRtcEtqY0pORG9sUzZBczRfN2o0cTdkOF9WSjdLZDVkeDllNjZ1WmRPY1pwU0l6UWVaOF9sVWFaeF…
CRBP — Frequently Asked Questions
What is the current share price of Corbus Pharmaceuticals Holdings, Inc. (CRBP)?
As of 2026-09-19 21:16 PDT, Corbus Pharmaceuticals Holdings, Inc. (CRBP) trades at $10.60 on NasdaqCM. Its 52-week range is $7.38 to $19.36.
What is the market capitalisation of CRBP?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a market capitalisation of $205.02M on NasdaqCM.
What is the P/E ratio of CRBP?
CRBP trades at a trailing price-to-earnings (P/E) ratio of -1.73. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.62.
What is the return on equity (ROE) of CRBP?
CRBP has a return on equity (ROE) of -95.58%. Its return on capital employed (ROCE) is -57.84%.
Is CRBP a good stock to buy?
This page provides a data-driven analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.